Literature DB >> 19303567

Recurrent Clostridium difficile infection: causality and therapeutic approaches.

Stuart Johnson1.   

Abstract

Recurrent diarrhoea after successful treatment of the primary episode is a common complication of Clostridium difficile infection (CDI) and may be increasing in frequency. Evidence suggests that persistent alterations in the indigenous bowel flora and failure to mount an effective antibody response to C. difficile toxins are the main mechanisms whereby recurrent CDIs occur. Treatment of the first recurrence with the same agent used for the treatment of the primary episode is reasonable, but a different approach is needed for patients with multiple CDI recurrences. Prolonged, repeated courses of metronidazole are discouraged, but a practical first option in these patients is to use tapered-dose oral vancomycin followed by a pulsed-dose regimen. Other potential options include probiotic approaches, restoration of the normal flora, immunological approaches, toxin-binding approaches, and serial therapy with vancomycin followed by rifaximin. Randomised studies including a sufficient numbers of patients have not yet been conducted for the treatment of recurrent CDI and are needed to help guide the formulation of effective recommendations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19303567     DOI: 10.1016/S0924-8579(09)70014-7

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  24 in total

Review 1.  Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection.

Authors:  L Patrick Schenck; Paul L Beck; Justin A MacDonald
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

Review 2.  Recurrent Clostridium difficile infection and the microbiome.

Authors:  Rowena Almeida; Teklu Gerbaba; Elaine O Petrof
Journal:  J Gastroenterol       Date:  2015-07-08       Impact factor: 7.527

Review 3.  Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance.

Authors:  Robert A Britton; Vincent B Young
Journal:  Trends Microbiol       Date:  2012-05-15       Impact factor: 17.079

4.  Is fidaxomicin worth the cost? An economic analysis.

Authors:  Sarah M Bartsch; Craig A Umscheid; Neil Fishman; Bruce Y Lee
Journal:  Clin Infect Dis       Date:  2013-05-23       Impact factor: 9.079

5.  Clostridium difficile colitis acquired in the intensive care unit: outcome and prognostic factors.

Authors:  L Sabau; A Meybeck; J Gois; P Devos; P Patoz; N Boussekey; P-Y Delannoy; A Chiche; H Georges; O Leroy
Journal:  Infection       Date:  2013-06-19       Impact factor: 3.553

Review 6.  Recurrent Clostridium difficile infection: what are the treatment options?

Authors:  Claire M F van Nispen tot Pannerden; Annelies Verbon; Ernst J Kuipers
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

7.  Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.

Authors:  Peter Warn; Pia Thommes; Abdul Sattar; David Corbett; Amy Flattery; Zuo Zhang; Todd Black; Lorraine D Hernandez; Alex G Therien
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

8.  Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.

Authors:  Zhiyong Yang; Jeremy Ramsey; Therwa Hamza; Yongrong Zhang; Shan Li; Harris G Yfantis; Dong Lee; Lorraine D Hernandez; Wolfgang Seghezzi; Jamie M Furneisen; Nicole M Davis; Alex G Therien; Hanping Feng
Journal:  Infect Immun       Date:  2014-12-08       Impact factor: 3.441

9.  Risk Factors for Recurrent Clostridium difficile Infections and Strategies to Decrease Readmissions in a Community Hospital.

Authors:  Darrin Majors; Patrick Ellis
Journal:  Hosp Pharm       Date:  2015-11-24

Review 10.  Inositol hexakisphosphate-induced autoprocessing of large bacterial protein toxins.

Authors:  Martina Egerer; Karla J F Satchell
Journal:  PLoS Pathog       Date:  2010-07-08       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.